Trial
NCT03316573
Pembrolizumab in Neoplasms or Lymphomas
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Merck Sharp & Dohme LLC
Condition
Lymphoma
Intervention
Pembrolizumab
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-10